Fluorodeoxyglucose positron emission tomography (FDG-PET) testing that shows early progression of patients with Ewing sarcoma is linked to reduced overall survival, according to an article published in the Journal of Clinical Oncology.1

Researchers analyzed data from a clinical trial evaluating the efficacy of a novel antibody; various evaluative measures for survival were analyzed to compare effectiveness.

Volume analysis and signals of early progression at day 9 predicted a worse overall survival rate. PET tests were more accurate predictors than anatomic imaging; volume analysis, however, was the best method of identifying which patients responded.

Continue Reading

RELATED: Sentinel Lymph Node Biopsy Recommended for Patients With Sarcoma

The authors conclude that although analyses of volume require validation, both volume analysis and activity noted with FDG-PET were the most likely to accurately predict the survival benefit of the tested antibody.


  1. Koshkin VS, Bolejack V, Schwartz LH, et al. Assessment of imaging modalities and response metrics in Ewing sarcoma: correlation with survival. J Clin Oncol. 2016 Aug 29. doi: 10.1200/JCO.2016.68.1858 [Epub ahead of print]